Renalytix Ai Plc ADR (RNLX) said before open Thursday that it lost $0.11 per share in quarter four 2023.
On the revenue line, the company reported $518 thousand, missing estimates by $202 thousand.
In the same quarter a year ago, the company lost $0.22 per share on revenue of $831 thousand.
The stock is down 33.67% to $1.30 after the report.
The firm's lower revenue growth to earnings signals that the firm has been able to reduce costs and improve its profit margin overall.
Wall Street Analysts had an average rating of Strong Buy on the stock prior to the report.
InvestorsObserver gives the stock a Bearish Sentiment score at the moment based on recent trading.
Prior to the report, InvestorsObserver gave the stock an overall score of 57. Meanwhile, the average Wall Street analyst rated the stock a Strong Buy.
Renalytix PLC is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. The company's lead product is KidneyIntelX which is being designed to make improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery.
News Home
Renalytix Ai Plc ADR Down 33.67% To $1.30 After Earnings Beat
Mentioned in this article
